[
    [
        {
            "time": "2023-10-04",
            "original_text": "A Handful of Start-Ups Are Developing Psychedelic Drugs for Mental Illnesses. It Could Be a Bad Trip for Investors.",
            "features": {
                "keywords": [
                    "psychedelic drugs",
                    "mental illnesses",
                    "start-ups",
                    "bad trip",
                    "investors"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]